Health experts predict uptick in U.S. Covid cases due to new BA.2 variant

Health experts predict uptick in U.S. Covid cases due to new BA.2 variant


Dr. Anthony Fauci, White House Chief Medical Advisor and Director of the NIAID, responds to questions from Sen. Rand Paul (R-KY) at a Senate Health, Education, Labor, and Pensions Committee hearing on Capitol Hill on January 11, 2022 in Washington, D.C.

Getty Images

U.S. health experts are warning an emerging, highly contagious Covid omicron variant, called BA.2, could soon lead to another uptick in domestic coronavirus cases.

White House chief medical advisor Dr. Anthony Fauci said BA.2 is about 50% to 60% more transmissible than omicron, but it does not appear to be more severe. Health officials continue to stress coronavirus vaccines and boosters remain the best ways to prevent serious illness from the virus.

“It does have increased transmission capability,” Fauci said Sunday on ABC’s “This Week.” “However, when you look at the cases, they do not appear to be any more severe and they do not appear to evade immune responses either from vaccines or prior infections.”

The variant has already caused cases to increase in China and parts of Europe. It is estimated to account for about 25% or 30% of new cases in the U.S., but it could become the country’s most dominant variant, Fauci said.

Fauci said he expects “an uptick in cases” due to BA.2, but not necessarily a massive surge like other variants have caused. That’s despite the Centers for Disease Control and Prevention recently relaxing mask recommendations for most Americans.

U.S. Surgeon General Vivek Murthy and Dr. Scott Gottlieb, a board member of Covid vaccine maker Pfizer and a former head of the Food and Drug Administration, also expressed similar views on Sunday regarding BA.2.

Murthy said the variant could cause a new spike in cases but that the country is in a better position now than it was in the previous two years, when Covid-19 “defined our lives.”

“We should be prepared, Covid hasn’t gone away,” Murthy said during “Fox News Sunday.” “Our focus should be on preparation, not on panic.”

Gottlieb, echoing previous comments days before to CNBC, said he also expects “some uptick” due to BA.2 but “not a big wave of infection.”

“I think we’re going to continue to see low levels of infection through the summer. But before we get there, we’re probably going to see some tick-up of infection like the Europeans are seeing right now, maybe not as pronounced,” Gottlieb said Sunday during CBS’s “Face the Nation.”

The CDC reported more than 31,200 new Covid-19 cases Saturday, including 958 deaths. Both are significantly down from the beginning of the year.

Disclosure: Scott Gottlieb is a CNBC contributor and is a member of the boards of Pfizer, genetic testing start-up Tempus, health-care tech company Aetion and biotech company Illumina. He also serves as co-chair of Norwegian Cruise Line Holdings’ and Royal Caribbean’s “Healthy Sail Panel.”



Source

Healthy Returns: AstraZeneca CEO proposes some U.S. drug price cuts amid Trump pressure
Health

Healthy Returns: AstraZeneca CEO proposes some U.S. drug price cuts amid Trump pressure

The office building of international biopharmaceutical company AstraZeneca. Cfoto | Future Publishing | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. President Donald Trump has been pressuring pharmaceutical companies to lower U.S. drug […]

Read More
Trump’s pharmaceutical tariffs could affect some drugmakers more than others
Health

Trump’s pharmaceutical tariffs could affect some drugmakers more than others

Medications are stored on shelves at a pharmacy on May 12, 2025 in Los Angeles, California. Eric Thayer | Getty Images President Donald Trump is slated to impose tariffs on pharmaceuticals imported into the U.S. any day now – and the duties may have a bigger impact on some drugmakers than others, according to some […]

Read More
Merck plans  billion cost cuts by end of 2027, narrows full-year outlook
Health

Merck plans $3 billion cost cuts by end of 2027, narrows full-year outlook

Merck & Co. signage on the floor of the New York Stock Exchange (NYSE) in New York, US, on Tuesday, April 8, 2025. Michael Nagle | Bloomberg | Getty Images Merck on Tuesday said it will slash $3 billion in costs by the end of 2027 to be fully reinvested to support new product launches […]

Read More